Elegrobart Phase 3 REVEAL-1 Trial Meets Primary Endpoint in Active Thyroid Eye Disease
VRDN sits 75% above its 52-week low of $9.9.
Summary
Viridian Therapeutics announced positive Phase 3 results for elegrobart in active thyroid eye disease, meeting its primary endpoint with high statistical significance and showing a favorable safety profile, positioning it as a potential first-in-class subcutaneous treatment.
Key Events · Product Development and Regulatory · VRDN
-
Elegrobart Phase 3 REVEAL-1 Trial Success
The REVEAL-1 clinical trial for elegrobart in active thyroid eye disease met its primary endpoint with high statistical significance (p < 0.0001) at week 24.
-
Clinically Meaningful Efficacy
Elegrobart achieved a 54% proptosis responder rate (Q4W) and 63% (Q8W) versus 18% for placebo, with 51% complete resolution of diplopia in the Q4W arm versus 16% placebo.
-
Favorable Safety Profile
The drug was generally well-tolerated, with low rates of hearing impairment (tinnitus) and no associated reductions in hearing.
-
Pipeline Advancement and Financial Strength
The company anticipates a Biologics License Application (BLA) submission for elegrobart in Q1 2027, following REVEAL-2 data in Q2 2026. Viridian also reported $875 million in cash as of Q4 2025, sufficient to fund operations through profitability.
Analysis · VRDN · Life Sciences
This 8-K announces highly positive topline results from the Phase 3 REVEAL-1 clinical trial for elegrobart in active thyroid eye disease (TED). The drug met its primary endpoint with high statistical significance, demonstrating robust proptosis responses and clinically meaningful improvements in diplopia. The favorable safety profile and potential for elegrobart to be the first subcutaneous autoinjector for TED represent a significant advancement and market opportunity. This successful trial de-risks a key pipeline asset and strengthens Viridian's position in the TED market, complementing its other late-stage candidate, veligrotug.
At the time of this filing, VRDN was trading at $17.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $9.90 to $34.29. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.